Clinical Trials

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04115631 2026-03-02

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

360 enrolled

Lymphoma, Mantle-Cell

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05057494 2026-02-18

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03946878 2026-02-17

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

32 enrolled

Lymphoma, Mantle-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

124 enrolled 10 charts 1 FDA

Lymphoma, Mantle-Cell

NCT02029443 2026-02-06

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

306 enrolled 26 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04624906 2026-02-04

BRAWM

63 enrolled

Waldenstrom Macroglobulinemia

NCT03932331 2026-01-29

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05583149 2026-01-29

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

28 enrolled 6 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT06205498 2026-01-22

ARISE

Active not recruiting

151 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02717624 2026-01-20

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

72 enrolled

Lymphoma, Mantle-Cell

NCT02586857 2026-01-12

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

CNSLymphoidOther hematologic neoplasm

24 enrolled 10 charts

Glioblastoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03328273 2026-01-12

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04604067 2025-12-30

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

260 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

12 enrolled

Waldenstrom Macroglobulinemia, Neuritis

NCT02180724 2025-11-26

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT04189757 2025-11-21

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

9 enrolled

Lymphoma, Mantle-Cell

NCT02477696 2025-11-20

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04765111 2025-11-10

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

53 enrolled

Lymphoma, Mantle-Cell

NCT04978584 2025-10-27

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05951959 2025-10-21

TrAVeRse

108 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

35 enrolled

Part1: Advanced B-cell Malignancies

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04722172 2025-08-27

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02157324 2025-08-13

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04546620 2025-08-06

REMoDL-A

453 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

500 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04657094 2025-04-27

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Classical hematologyLymphoidOther hematologic neoplasm

4 enrolled 7 charts

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 1 FDA